ARS Pharmaceuticals Showcases Neffy Equivalence to 0.5mg Injected Epinephrine, 25% Value Gain
ARS Pharmaceuticals will present seven studies at the AAAAI Annual Meeting, including five neffy poster presentations and two ALK-Abelló late breakers, highlighting pharmacokinetic equivalence of 2 mg nasal spray to 0.5 mg intramuscular epinephrine and health-economic analyses. Data show neffy’s longer shelf life enables a more affordable price and boosts patient preference value by over 25%.
1. Presentation Overview
ARS Pharmaceuticals will feature five poster presentations, one healthcare professional case report and two late-breaking partner studies at the 2026 AAAAI Annual Scientific Meeting in Philadelphia from February 27 to March 2. The sessions cover health-economic analyses, usability research and pharmacokinetic comparisons of neffy versus injectable epinephrine.
2. Pharmacokinetic and Economic Data
Studies demonstrate that a 2 mg neffy dose achieves systemic exposure similar to a 0.5 mg intramuscular injection while offering longer shelf life. Health-economic analyses indicate that neffy’s extended stability translates into lower costs, supporting its potential as a cost-effective alternative.
3. Patient Preference and Usability
Research on treatment preference shows patients and caregivers favor neffy’s needle-free delivery, with needle aversion driving a more than 25% increase in perceived value. Usability assessments highlight simple administration and reliability in emergency scenarios.
4. Event Logistics
Attendees can view all neffy presentations in Convention Center Level 2, Hall E, visit booth #737 and participate in a Non-CME Problem Based Learning session on February 26 titled “Reimagining Epinephrine Administration with Epinephrine Nasal Spray.”